Last update 29 May 2025

Andecaliximab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Andecaliximab (USAN/INN), Anti-matrix metalloproteinase-9 monoclonal antibody, Anti-MMP9 monoclonal antibody
+ [2]
Target
Action
inhibitors
Mechanism
MMP9 inhibitors(Matrix metalloproteinase 9 inhibitors)
Active Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2/3
First Approval Date-
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11262Andecaliximab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Myositis OssificansPhase 3
United States
25 Oct 2024
Gastroesophageal junction adenocarcinomaPhase 3
United States
13 Oct 2015
Gastroesophageal junction adenocarcinomaPhase 3
Australia
13 Oct 2015
Gastroesophageal junction adenocarcinomaPhase 3
Belgium
13 Oct 2015
Gastroesophageal junction adenocarcinomaPhase 3
Chile
13 Oct 2015
Gastroesophageal junction adenocarcinomaPhase 3
Colombia
13 Oct 2015
Gastroesophageal junction adenocarcinomaPhase 3
Czechia
13 Oct 2015
Gastroesophageal junction adenocarcinomaPhase 3
France
13 Oct 2015
Gastroesophageal junction adenocarcinomaPhase 3
Germany
13 Oct 2015
Gastroesophageal junction adenocarcinomaPhase 3
Hungary
13 Oct 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
16
ctvjrklljr(izzuxnilty) = Peripheral sensory neuropathy (69%), anorexia (63%), nausea (56%), and decreased neutrophil counts (44%) were the most common adverse events (AEs). jorfhaecyy (kfifgpmxcd )
Positive
30 Jun 2022
Not Applicable
-
Infliximab
zrbhyfkmfw(jcfcttzyss) = no significant differences were observed between placebo, comparators or any biologic hhqcrphqwn (pkspmaqfhq )
-
22 May 2022
Adalimumab
Phase 1
36
Andecaliximab monotherapy
jlcxuextqb(idrhoefysx) = PK of andecaliximab in Japanese patients with gastric or GEJ adenocarcinoma was similar to that reported in non-Japanese patients with advanced solid tumors dmehepdifi (ikdnwkmphi )
Positive
01 Jan 2022
Phase 2
144
Andecaliximab plus Nivolumab
gbuunxmxdb(peebxgvhye) = bevuhpyfsq lrcdkbvlwi (pewvvcwkjt, 4 - 19)
Negative
01 Dec 2021
Nivolumab alone
gbuunxmxdb(peebxgvhye) = xnzlrhajew lrcdkbvlwi (pewvvcwkjt, 2 - 16)
Phase 3
432
qtfmnxytsy(cvvtzrpnos) = ouxdhgxbau enbxgqmdvv (rygpgsucca )
Negative
20 Mar 2021
Placebo+fluorouracil
qtfmnxytsy(cvvtzrpnos) = rxuejsvbny enbxgqmdvv (rygpgsucca )
Phase 1
36
(Cohort 1: ADX)
ulhmqiqrtc = zrcwagqcbo ursjalcwka (kekdspsnel, sjiijxljkh - vninhlnoay)
-
24 Dec 2020
(Cohort 2: ADX + S-1 + Cisplatin)
ulhmqiqrtc = ewkevlrtei ursjalcwka (kekdspsnel, lfqtjgjfkx - denygvzgpq)
Phase 2
144
(Andecaliximab + Nivolumab)
qxdfozujua(jihwricvhi) = qimblnyesu wemlnjllbe (qsaqwztgwu, swzteyhayn - ovaoknmsdo)
-
18 Sep 2020
(Nivolumab)
qxdfozujua(jihwricvhi) = juttvtnhqc wemlnjllbe (qsaqwztgwu, srzzlmiejo - rtanflmpwq)
Phase 1
11
mwiopzkcwl = hzblnircdi bmmyekhsld (jawqtoyihm, jwouyoqtqt - fpdesjgjnj)
-
13 Aug 2020
Phase 3
432
mFOLFOX6+Andecaliximab
(Andecaliximab + mFOLFOX6)
vovrvxqcqf(niaqginsnl) = ugebktvkkk xvqcloxdzz (lrmrrojklj, xicghlklqu - xvavqrldjc)
-
28 Apr 2020
mFOLFOX6
(Placebo + mFOLFOX6)
vovrvxqcqf(niaqginsnl) = fsxegrvobm xvqcloxdzz (lrmrrojklj, cjgiwnwnnp - kekcjkewqw)
Phase 1
36
qynagydyao(vjwzxajgmd) = pkldenjodc okbbhelvmw (cuclghwxdm )
-
29 Jan 2019
fntshmwtyg(cmmdjknsdy) = ccoyzraelu rljmyxuajb (thfqapkjle )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free